首页|血府逐瘀汤治疗急性脑梗死的系统评价及Meta分析

血府逐瘀汤治疗急性脑梗死的系统评价及Meta分析

扫码查看
目的 系统评价血府逐瘀汤治疗急性脑梗死的临床效果及安全性,为血府逐瘀汤治疗急性脑梗死提供循证医学证据.方法 计算机检索PubMed、万方数据库、中国知网(CNKI)、中文科技期刊数据库(VIP)中有关血府逐瘀汤治疗急性脑梗死的随机对照试验,文献检索的年限为各数据库建库至2024年5月,采用Cochrane风险评估表评价其质量,通过RevMan5.4软件提取资料进行敏感性分析和发表偏倚分析,并进行Meta分析.结果 共纳入19项临床随机对照试验,共有1 856例患者,Meta分析结果显示,应用血府逐瘀汤联合西医常规处理治疗急性脑梗死,临床总有效率高于单纯西医治疗[比值比(OR)=4.84,95%CI(3.39,6.91),Z=8.69,P<0.000 01];美国国立卫生研究院卒中量表(NIHSS)评分[均数差(MD)=-5.10,95%CI(-6.72,-3.48),Z=6.16,P<0.000 01]、日常生活质量量表(ADL)评分[标准化均数差(SMD)=2.92,95%CI(1.68,4.17),Z=4.60,P<0.00001]、血浆黏稠度[MD=-0.27,95%CI(-0.37,-0.17),Z=5.28,P<0.00001]、纤维蛋白原[MD=-1.03,95%CI(-1.40,-0.66),Z=5.50,P<0.00001]、肿瘤坏死因子-α[MD=-14.47,95%CI(-18.78,-10.16),Z=6.58,P<0.000 01]、超敏 C 反应蛋白[MD=-1.72,95%CI(-2.18,-1.26),Z=7.28,P<0.000 01]等 指标的改善程度优于单纯西医治疗,差异均具有统计学意义.结论 现有证据表明,应用血府逐瘀汤联合西医常规处理治疗急性脑梗死的临床疗效优于单纯西医常规处理,但还需要高质量的临床研究加以佐证.
Meta-analysis and Systematic Review of Xuefu Zhuyu Decoction in the Treatment of Acute Cerebral Infarction
Objective:To systematically evaluate the clinical efficacy and safety of Xuefu Zhuyu Decoction in the treatment of acute cerebral infarction,and to provide evidence-based medical evidence for Xuefu Zhuyu Decoc-tion in the treatment of acute cerebral infarction.Methods:A computerized search was performed for randomized controlled trials(RCTs)on the treatment of acute cerebral infarction with Xuefu Zhuyu Decoction in PubMed,Wan-fang database,China National Knowledge Infrastructure(CNKI),and VIP from the inception of database to March 2024.Cochrane Risk Assessment Scale was used to evaluate the quality of the studies.Data were extracted using RevMan 5.4 software for sensitivity analysis and publication bias analysis,followed by a meta-analysis.Results:A total of 19 RCTs involving 1856 patients were included.Meta-analysis showed that the combined use of Xuefu Zhuyu Decoction with basic western medicine treatment for acute cerebral infarction had a higher overall clinical efficacy rate compared with western medicine alone[OR=4.84,95%CI(3.39,6.91),Z=8.69,P<0.000 01];im-provement in NIH Stroke Scale(NIHSS)scores[MD=-5.10,95%CI(-6.72,-3.48),Z=6.16,P<0.000 01];Ac-tivities of Daily Living(ADL)scores[SMD=2.92,95%CI(1.68,4.17),Z=4.60,P<0.000 01];plasma viscosity[MD=-0.27,95%CI(-0.37,-0.17),Z=5.28,P<0.000 01];fibrinogen levels[MD=-1.03,95%CI(-1.40,-0.66),Z=5.50,P<0.000 01];tumor necrosis factor-alpha(TNF-α)levels[MD=-14.47,95%CI(-18.78,-10.16),Z=6.58,P<0.000 01];and high-sensitivity C-reactive protein(hs-CRP)levels[MD=-1.72,95%CI(-2.18,-1.26),Z=7.28,P<0.000 01]were significantly better than those treated with western medicine alone,and the differenc-es were all statistically significant.Conclusion:The available evidence suggests that the clinical efficacy of apply-ing Xuefu Zhuyu Decoction combined with western medicine in the treatment of acute cerebral infarction is superi-or to that of applying western medicine therapy alone,but high-quality clinical studies are needed to support this finding.

Acute ischemic strokeXuefu Zhuyu DecoctionMeta-analysisSystematic review

姜宏儒、周锋、付晓曼、李雄、张佳云

展开 >

陕西中医药大学,陕西 咸阳 712000

陕西中医药大学附属医院,陕西 咸阳 712000

急性脑梗死 血府逐疲汤 Meta分析 系统评价

国家自然科学基金面上项目国家自然科学基金面上项目国家中医药创新骨干人才项目陕西中医药大学科技创新人才体系建设计划项目

8187338782074552[2019]128号2023-CXTD-02

2024

中国中医急症
中华中医药学会

中国中医急症

CSTPCD
影响因子:1.144
ISSN:1004-745X
年,卷(期):2024.33(10)
  • 28